v3.26.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2025
Revenue  
Schedule of revenue recognized

The following schedule entails detailed information about the Group’s revenue in the financial year 2025:

​

​

​

​

​

​

​

​

​

Discovery &

​

​

​

​

​

​

Preclinical

​

Just - Evotec

​

​

in k€

  ​ ​ ​

Development

  ​ ​ ​

Biologics

  ​ ​ ​

Evotec Group

Revenue from contracts with customers

 

  ​

 

  ​

 

  ​

Fee for services and FTE-based research services

 

468,515

 

144,412

 

612,927

Material re-charges to customers

 

31,892

 

—

 

31,892

Milestone fees

 

9,615

 

—

 

9,615

Licenses

 

7,314

 

115,031

 

122,345

Other fees

 

300

 

—

 

300

Total revenue from contracts with customers

 

517,636

 

259,443

 

777,079

Timing of revenue recognition

 

​

 

​

 

​

At a point in time

 

49,121

 

115,031

 

164,152

Over a period of time

 

468,515

 

144,412

 

612,927

Total revenue from contracts with customers

​

517,636

​

259,443

​

777,079

Revenue from contributions

​

11,294

​

—

​

11,294

Total Revenue

 

528,930

 

259,443

 

788,373

​

​

The following schedule entails detailed information about the Group’s revenue in the financial year 2024:

​

​

​

​

​

​

​

​

​

Discovery &

​

​

​

​

​

​

Preclinical

​

Just - Evotec

​

​

in k€

  ​ ​ ​

Development

  ​ ​ ​

Biologics

  ​ ​ ​

Evotec Group

Revenue from contracts with customers

 

  ​

 

  ​

 

  ​

Fee for services and FTE-based research services

 

553,963

 

183,431

 

737,394

Material re-charges to customers

 

38,578

 

—

 

38,578

Milestone fees

 

2,871

 

—

 

2,871

Licenses

 

3,130

 

—

 

3,130

Other fees

 

544

 

—

 

544

Total revenue from contracts with customers

 

599,086

 

183,431

 

782,517

Timing of revenue recognition

 

​

 

​

 

​

At a point in time

 

83,157

 

44,123

 

127,280

Over a period of time

 

515,929

 

139,308

 

655,237

Total revenue from contracts with customers

​

599,086

​

183,431

​

782,517

Revenue from contributions

​

12,308

​

2,142

​

14,450

Total Revenue

 

611,394

 

185,573

 

796,967

​

The following schedule entails detailed information about the Group’s revenue in the financial year 2023:

​

​

​

​

​

​

​

​

​

Discovery &

​

​

​

​

​

​

Preclinical

​

Just - Evotec

​

​

in k€

  ​ ​ ​

Development

  ​ ​ ​

Biologics

  ​ ​ ​

Evotec Group

Revenue from contracts with customers

 

  ​

 

  ​

 

  ​

Fee for services and FTE-based research services

 

619,437

 

107,492

 

726,929

Material re-charges to customers

 

37,561

 

—

 

37,561

Milestone fees

 

4,785

 

—

 

4,785

Licenses

 

674

 

1

 

675

Other fees

 

2,059

​

—

 

2,059

Total revenue from contracts with customers

 

664,516

 

107,493

 

772,009

Timing of revenue recognition

 

​

 

​

 

​

At a point in time

 

42,345

 

46,242

 

88,587

Over a period of time

 

622,171

 

61,251

 

683,421

Total revenue from contracts with customers

 

664,516

​

107,493

​

772,009

Revenue from contributions

​

8,461

​

956

​

9,417

Total Revenue

​

672,977

 

108,449

 

781,426

​

Schedule of transaction price allocated to the remaining performance obligation

​

​

​

​

​

​

​

​

in k€

  ​ ​ ​

December 31, 2025

  ​ ​ ​

December 31, 2024*

  ​ ​ ​

December 31, 2023

In the course of the following year

 

258,618

​

460,835

 

571,825

After one year

 

190,240

​

885,577

 

335,427

*Change from prior year disclosed amount

Schedule of contract assets and contract liabilities

​

​

​

​

​

​

in k€

  ​ ​ ​

2025

  ​ ​ ​

2024

Balance as of January 1

 

46,034

 

25,000

Additions

 

263,025

 

201,016

Reclassifications to trade receivables due to invoicing

 

(275,559)

 

(181,469)

Translation differences and other

 

(5,205)

 

1,487

Balance as of December 31

 

28,295

 

46,034

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Current

  ​ ​ ​

Non-current

in k€

  ​ ​ ​

2025

  ​ ​ ​

2024

​

2025

  ​ ​ ​

2024

Balance as of January 1

  ​ ​ ​

106,599

  ​ ​ ​

97,587

  ​ ​ ​

156,679

  ​ ​ ​

155,287

Additions

 

141,168

 

220,121

 

69,649

 

94,574

Reduction due to recognition of revenue

 

(222,724)

 

(303,748)

 

—

 

—

Divestment of affiliated companies

​

—

​

(1,069)

​

—

​

—

Reclassification from non-current to current

 

81,004

 

93,181

 

(81,004)

 

(93,182)

Translation differences and other

 

(1,198)

 

526

 

—

 

—

Balance as of December 31

 

104,849

 

106,599

 

145,324

 

156,679

​